ALS Network

ALS Network is a non-profit organization dedicated to partnering with the ALS community to advance the discovery of prevention strategies, treatments, and cures for Amyotrophic Lateral Sclerosis (ALS). The organization also focuses on providing access to quality care and connection, and promoting initiatives to improve health outcomes for those affected by the disease. Headquartered in Woodland Hills, California, ALS Network serves individuals and families across California and Hawaii.

The organization offers a comprehensive suite of services, including professional care management, access to ALS clinics and equipment loan programs, and various support and educational resources for patients, caregivers, and families. ALS Network is also a significant driver of ALS research, spearheading and funding collaborative initiatives, and actively engaging in advocacy efforts to influence public policy and accelerate scientific discovery.

In recent news, ALS Network announced its strategic integration with ALS ONE in February 2026, aiming to accelerate research and expand care through enhanced technology and collaboration. The organization also voiced support for the ACT for ALS Reauthorization Act in May 2026. Sheri Strahl, MPH, MBA, assumed the role of President and CEO on February 1, 2024, leading the organization through a period of significant growth and strategic rebranding from its former identity as ALS Golden West and The ALS Association Golden West Chapter.

Latest updates

Senate Introduces Bill to Extend ALS Therapy Access Program

Event summary

  • The Accelerating Access to Critical Therapies (ACT) for ALS Act (S.4472/H.R.8205) has been reintroduced in the Senate.
  • The bipartisan bill, led by Senators Murkowski and Coons, aims to reauthorize the program through 2031.
  • ACT for ALS focuses on accelerating ALS research and expanding access to investigational therapies outside of traditional clinical trials.
  • Advocates, including the ALS Network and ALS United, plan to lobby Congress on May 6th to secure reauthorization.

The big picture

The ACT for ALS Act represents a critical bridge for patients facing a devastating disease with few treatment options. Its reauthorization underscores the ongoing tension between accelerating access to experimental therapies and maintaining rigorous regulatory oversight. The bill's fate will signal the legislature's commitment to supporting rare disease research and patient-centered innovation.

What we're watching

Legislative Process
The bill's progress through the Senate will depend on broader political dynamics and the appetite for healthcare-related legislation, potentially facing delays or amendments.
Patient Impact
The continued availability of investigational therapies hinges on reauthorization, directly impacting patients with limited treatment options and highlighting the urgency of congressional action.
Research Ecosystem
The pace at which research infrastructure can maintain momentum will be affected by the bill's passage, potentially influencing the timeline for new treatment discoveries.
CID: 862